{
    "doi": "https://doi.org/10.1182/blood.V116.21.2423.2423",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1869",
    "start_url_page_num": 1869,
    "is_scraped": "1",
    "article_title": "Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group ",
    "article_date": "November 19, 2010",
    "session_type": "CLL - Biology and Pathophysiology, excluding Therapy: Poster II",
    "topics": [
        "chronic b-cell leukemias",
        "chronic lymphocytic leukemia",
        "cancer",
        "immunoglobulins",
        "receptors, antigen, b-cell",
        "sequence analysis"
    ],
    "author_names": [
        "Francesco Maura",
        "Giovanna Cutrona, PhD",
        "Massimo Gentile",
        "Serena Matis, PhD",
        "Monica Colombo",
        "Luca Agnelli",
        "Giacomo Tuana",
        "Rosanna Massara",
        "Fabrizio Loiacono",
        "Simona Pedemonte",
        "Daniele Reverberi",
        "Emanuela Anna Pesce",
        "Marta Lionetti, PhD",
        "Sonia Fabris, PhD",
        "Anna Grazia Recchia",
        "Francesco Di Raimondo, MD",
        "Caterina Musolino, MD",
        "Marco Gobbi",
        "Nicola Di Renzo, MD",
        "Francesca Romana Mauro",
        "Renato Cantaffa",
        "Maura Brugiatelli, MD",
        "Francesco Merli, MD",
        "Simonetta Zupo",
        "Caterina Mammi",
        "Luca Baldini",
        "Francesco Angrilli, MD",
        "Gianni Quintana",
        "Ugo Consoli, MD",
        "Giovanni Bertoldero, MD",
        "Emilio Iannitto, MD",
        "Paolo Di Tonno",
        "Antonio Fragasso",
        "Stefano Molica, MD",
        "Pellegrino Musto, MD",
        "Maria Cristina Cox",
        "Gianluca Festini",
        "Vincenzo Callea, MD",
        "Stefano Sacchi",
        "Giorgio Lambertenghi Deliliers, MD",
        "Robin Foa\u0300, MD",
        "Massimo Federico, MD",
        "Agostino Cortelezzi, MD",
        "Fortunato Morabito",
        "Manlio Ferrarini",
        "Antonino Neri, MD"
    ],
    "author_affiliations": [
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "GISL Trial Office, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Dipartimento di Farmacologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Fondazione Matarelli, Milano, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy, "
        ],
        [
            "Ematologia, Universita\u0300 di Catania, Catania, Italy, "
        ],
        [
            "University of Messina, Hematology Section, Messina, Italy, "
        ],
        [
            "Ematologia, Universita\u0300 di Genova, Genova, "
        ],
        [
            "Unita\u0300 di Ematologia, Ospedale Vito Fazzi, Lecce, Italy, "
        ],
        [
            "Divisione di Ematologia, Universita\u0300 La Sapienza, Roma, Italy, "
        ],
        [
            "Divisione di Ematologia, Azienda Ospedaliera Catanzaro, Catanzaro, Italy, "
        ],
        [
            "Azienda Ospedaliera Papardo, Divisione Di Ematologia, Messina, Italy, "
        ],
        [
            "Ematologia, Azienda Ospedaliera S.Maria Nuova, Reggio Emilia, Italy, "
        ],
        [
            "SS Malattie Linfoproliferative, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Ematologia, Azienda Ospedaliera S.Maria Nuova, Reggio Emilia, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Ematologia, Ospedale Santo Spirito, Pescara, Italy, "
        ],
        [
            "Divisione di Ematologia, Presidio Ospedaliero A.Perrino, Brindisi, Italy, "
        ],
        [
            "Oncology, Divisione di Ematologia, Ospedale Garibaldi Nesima, Catania, Italy, Catania, Italy, "
        ],
        [
            "Oncologia ed Ematologia Clinica, Ospedale Civile di Mirano, Mirano, Italy, "
        ],
        [
            "Divisione di Ematologia, Ospedale Policlinico, Palermo, Italy, "
        ],
        [
            "Dipartimento di Ematologia,Venere, Ospedale Bari Carbonara, Bari, "
        ],
        [
            "Unita\u0300 Operativa di Medicina Interna, Presidio Ospedaliero di Matera, Matera, Italy, "
        ],
        [
            "Oncologia Medica, Az. Ospedaliera Pugliese Ciaccio, Catanzaro, Italy, "
        ],
        [
            "Onco-Hematology, Department of Hematology, Scientific Institute of Research and Cure, Reference Cancer Center of Basilicata, Rionero in Vulture, Rionero in Vulture (Pz), Italy, "
        ],
        [
            "Ematologia, A.O. Sant'Andrea, Universita' La Sapienza, Roma, Italy, "
        ],
        [
            "Centro di Riferimento Ematologico-Seconda Medicina, Azienda Ospedaliero-Universitaria, Ospedali Riuniti, Trieste, Italy, "
        ],
        [
            "Institute of Hematology- Reggio Calabria, Italy, Italy, "
        ],
        [
            "Oncologia ed Ematologia, Universita\u0300 di Modena, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Institute of Hematology, Department of Cellular Biotechnologies and Hematology, \u201cSapienza\u201d University of Rome, Roma, Italy, "
        ],
        [
            "Dip. Integrato di Onc./Em., Centro Oncologico Modenese, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, UniversitA\u0303 di Milano, Milano, Italy"
        ]
    ],
    "first_author_latitude": "45.459492600000004",
    "first_author_longitude": "9.19477725",
    "abstract_text": "Abstract 2423 Chronic lymphocytic leukemia (CLL) is characterized by an extremely variable clinical course. Mutational status of the immunoglobulin heavy-chain variable (IGHV) region defines two disease subsets with different prognosis. A fraction of CLL cases carries highly homologous B-cell receptors (BCR), i.e. characterized by non-random combinations of immunoglobulin heavy-chain variable (IGHV) genes and heavy-chain complementarity determining region-3 (HCDR3). We performed sequence analysis to characterize IGHV regions in a panel of 1133 CLL patients investigated by a multicenter Italian study group. A total of 1148 rearrangements were identified; the analysis of stereotyped subsets was performed based on previously reported criteria (Messmer et al , J Exp Med 2004; Stamatopuolos et al , Blood 2007). Specifically, we compared all our sequences with those found in three different publicly available data sets (Stamatopoulos et al , Blood 2007; Murray et al , Blood 2008 and Rossi et al , 2009 Clin Cancer Res). In addition, a pairwise alignment within all sequences was performed in order to discover novel potential subsets (HCDR3 identity > 60%). Based on the 2% cut-off used to discriminate between Mutated (M) and Unmutated (UM) cases, 777 sequences (67.59%) were classified as M, while 371 sequences (32.3%) as UM. The most represented IGHV genes within mutated cases were IGHV4-34 (104/118) and IGHV3-23 (85/96), whereas IGHV1-69 (97/112) was the most frequently used in the UM group. Interestingly, the IGHV3-21 gene, reported to be frequently expressed in CLL patients from Northern Europe, was present in only a small fraction of cases (24; 2.07%), confirming a previous finding reported by Ghia et al (Blood 2005) in a smaller panel. In our series, stereotyped HCDR3 sequences were found in 407/1148 (35.45%) patients, 177 of whom were M and 230 were UM cases. Overall, we observed that stereotyped sequences were significantly associated with UM IGHV status (Fisher's exact test, P <0.0001). Among the 407 stereotyped HCDR3 sequences, 345 belong to the clusters reported by Murray et al and 14 to those described by Rossi et al ., 2009 Clin Cancer Res. The most frequent stereotyped subsets identified in our panel were #1 (35 cases), #7 (28 cases), #4 (24 cases), #3 and #9 (16 cases), #28 (13 cases), and #2 (12 cases), together with subsets #5, #8, #10, #12, #13, #16 and #22 (all ranging from 6 to 9 cases). Finally, we were able to identify by auto-matching analysis 48 sequences potentially specific for 23 novel putative stereotype subsets. In our series we identified 407/1148 (35.45%) stereotyped HCDR3 sequences. The percentage was higher than that reported by Stamatopoulos et al and Murray et al . This discrepancy may partially be due to the different approach used in our analysis, namely the matching to a general data set including all published stereotyped subsets instead of the auto-matching performed by those Authors. We demonstrated a significant association between IGHV status and stereotyped sequences and confirmed the finding that #1 is the most frequent subset identified so far. Finally, we were able to identify a series of 23 novel putative subsets that will require further confirmation. Disclosures: No relevant conflicts of interest to declare."
}